Quotes

Back To Menu

Nippon India Pharma Fund (IDCW) Equity - Pharma
Invest

Plan: OPEN | Option: Dividend | Sailesh Raj Bhan

26 Nov 21 | 12:00 AM

88.79 1.01 (1.15%)

  • Outperforms

    30.05%

    Return (1Y)

    beaten S&P BSE Healthcare TRI by 5.75%

  • Less Volatile

    1.02%

    Standard Deviation (1Y)

    Lower Equity - Pharma by -0.29%

  • Consistent

    7/12

    Months

    Has beaten Equity - Pharma

  • Value research rating

    Not Rated

Stock Composition

NAV

Critical Parameters

Everyone of us wants to create wealth by investing in top funds. Have a look at the key parameters that you need to check before deciding to invest in a mutual fund.

Returns

In last 1 year Nippon India Pharma Fund (IDCW), has beaten by 5.75% (CAGR difference)

30.05%

Outperforms

This is Alpha

Performance Chart for Rs

Invested in

30 Nov 2020

Risk

In last 1 year , the volatility of Nippon India Pharma Fund (IDCW) is Lower than by -0.29%

1.02%

Less Volatile

Risk Meter

Peer Comparison on Risk - Return

Consistency

For 7 out of Last 12 Months, i.e 58.33% of the times It beaten its benchmark, Equity - Pharma

Consistency Meter

Outperforming Stocks Vs. Underperforming Stocks

Based on the last 1year analysis, currently there are, the benchmark the benchmark

View Stock Composition